Teewinot Life Sciences Corporation is propelling its path at becoming the global leader in the development of cannabinoid-based pharmaceuticals. Teewinot Life Sciences and Full Spectrum Laboratories, Ltd. (FSL), a wholly owned subsidiary of Teewinot, officially announced the grant of U.S. Patent No. 9,587,212 (“the ‘212 patent”) entitled Apparatus and Methods for Biosynthetic Production of Cannabinoids. The ‘212 patent has broad claims to a system for production of cannabinoids using cannabinoid biosynthetic enzymes expressed in microorganisms transformed with cannabinoid biosynthetic genes. FSL’s proprietary processes are used to manufacture kilogram quantities of a wide range of pharmaceutically pure cannabinoids such as THCA, THC, THCVA, THCV, CBDA, CBD, CBDVA, CBDV, CBCA, CBC, CBCVA, CBCV, CBGA, CBG, CBGVA, and CBGV.
The ‘212 patent claims the ability to cover the genetic engineering with genes cloned of microorganisms from the Cannabis. Which then produces commercial quantities of pharmaceutically pure cannabinoids through the use of the genetically engineered microorganisms and the code of cannabinoid biosynthetic enzymes. The ‘212 patent is an important addition to FSL’s increasingly valuable patent portfolio.”
Teewinot has also developed a variety of services and products that rely on the technologies developed to create an efficient and cost-effective production of authentic cannabinoids. Along with, cannabinoid prodrugs and cannabinoid analogs. When combining synthetic biology, biocatalysis, chemical synthesis and bioinformatics and metabolomics, these certain cannabinoids developed now have the exact chemical structure of cannabinoids that are in the cannabis plant.
Another advantage of these methods is that cannabinoid prodrugs and cannabinoid analogs can be provided without the generation of significant amounts of chemical waste associated with multi-step chemical synthesis and in a highly pure form.
Leading universities and pharmaceutical companies have partnered with Teewinot to work on the development of the proprietary compounds into clinics to provide these therapies.
Teewinot is interested in seeking partners that want to work with their company to commercialize these primary cannabinoids and provide patients with new healthcare solutions.